252 related articles for article (PubMed ID: 14511566)
1. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy.
Cheung NK; Guo HF; Modak S; Cheung IY
Hybrid Hybridomics; 2003 Aug; 22(4):209-18. PubMed ID: 14511566
[TBL] [Abstract][Full Text] [Related]
2. Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins.
Cheung NK; Guo HF; Modak S; Cheung IY
Hybrid Hybridomics; 2002 Dec; 21(6):433-43. PubMed ID: 12573107
[TBL] [Abstract][Full Text] [Related]
3. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.
Reinhold U; Liu L; Lüdtke-Handjery HC; Heuser C; Hombach A; Wang X; Tilgen W; Ferrone S; Abken H
J Invest Dermatol; 1999 May; 112(5):744-50. PubMed ID: 10233766
[TBL] [Abstract][Full Text] [Related]
4. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
Moritz D; Groner B
Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604
[TBL] [Abstract][Full Text] [Related]
5. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.
Mamalaki A; Gritzapis AD; Kretsovali A; Belimezi M; Papamatheakis J; Perez SA; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Aug; 52(8):513-22. PubMed ID: 12715240
[TBL] [Abstract][Full Text] [Related]
7. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
[TBL] [Abstract][Full Text] [Related]
8. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
[TBL] [Abstract][Full Text] [Related]
9. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.
Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ; Darcy PK
J Immunol; 2001 Jan; 166(1):182-7. PubMed ID: 11123291
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
11. Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCR zeta.
Annenkov A; Chernajovsky Y
Gene Ther; 2000 Apr; 7(8):714-22. PubMed ID: 10800096
[TBL] [Abstract][Full Text] [Related]
12. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene.
Daly T; Royal RE; Kershaw MH; Treisman J; Wang G; Li W; Herlyn D; Eshhar Z; Hwu P
Cancer Gene Ther; 2000 Feb; 7(2):284-91. PubMed ID: 10770638
[TBL] [Abstract][Full Text] [Related]
13. Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor.
Turatti F; Figini M; Alberti P; Willemsen RA; Canevari S; Mezzanzanica D
J Gene Med; 2005 Feb; 7(2):158-70. PubMed ID: 15538730
[TBL] [Abstract][Full Text] [Related]
14. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
Arakawa F; Shibaguchi H; Xu Z; Kuroki M
Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
[TBL] [Abstract][Full Text] [Related]
15. Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions.
López-Requena A; Mateo de Acosta C; Pérez A; Valle A; Lombardero J; Sosa K; Pérez R; Vázquez AM
Hybrid Hybridomics; 2003 Aug; 22(4):235-43. PubMed ID: 14511569
[TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
Altenschmidt U; Klundt E; Groner B
J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
[TBL] [Abstract][Full Text] [Related]
17. The T-body approach: redirecting T cells with antibody specificity.
Eshhar Z
Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
[TBL] [Abstract][Full Text] [Related]
18. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
19. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma.
Darcy PK; Kershaw MH; Trapani JA; Smyth MJ
Eur J Immunol; 1998 May; 28(5):1663-72. PubMed ID: 9603473
[TBL] [Abstract][Full Text] [Related]
20. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
